Impact of psychotropic medications on simulated driving: a critical review.

Mark J Rapoport, Melanie C Baniña
Author Information
  1. Mark J Rapoport: Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. mark.rapoport@sunnybrook.ca

Abstract

Driving a motor vehicle is central to the functional autonomy of patients with psychiatric illnesses. There have been many studies of the deleterious effects of psychotropic medications such as benzodiazepines, typical antipsychotics and tricyclic antidepressants (TCAs) on human motor skills; however, in the literature little attention has been paid to how such impairment affects driving ability. Computerised driving simulators offer a laboratory-based method of assessing the effects of specific psychotropic medications on driving abilities, in a standardised, controlled and safe manner. The purpose of the present article is to review research undertaken to-date on the effects of psychotropic medications on computer-simulated driving. A search of various databases, including MEDLINE, EMBASE and PsycInfo, was conducted. Forty-one articles assessing the impact of psychotropics on computer-simulated driving were identified. The pooled total number of subjects assessed in these simulator studies was 1336 (mean sample size 30.36 [SD 35.8]). The most common outcome measures in the various studies were speed, steering, deviation from lateral position (tracking, lane drifting), reaction time or braking accuracy, driving errors (e.g. errors in turning, coordination, gap acceptance, signalling, following distance) and vehicle collisions. The results of the studies were quite variable; however, the most common drug-related impairments included those of tracking and reaction time. Benzodiazepines and TCAs were most commonly associated with impairment, although the level of impairment was dependent on the population studied, the dose and the time of testing relative to drug administration. Computer-simulated driving provides a useful tool to research psychotropic-related impairment of driving abilities. Limitations of currently available data include the lack of generalisability, standardisation and small sample sizes.

References

  1. Psychopharmacology (Berl). 1977 Mar 23;52(1):103-6 [PMID: 15295]
  2. Can Fam Physician. 1998 Apr;44:799-808 [PMID: 9585853]
  3. Br J Clin Pharmacol. 1993 Jul;36(1):67-70 [PMID: 8104017]
  4. Pharmacopsychiatry. 1984 Mar;17(2):36-43 [PMID: 6145169]
  5. Am J Geriatr Psychiatry. 2005 Oct;13(10):892-900 [PMID: 16223968]
  6. Br J Psychiatry. 1990 Aug;157:275-8 [PMID: 2121308]
  7. Ann Med Exp Biol Fenn. 1973 Mar;51(3):125-32 [PMID: 4590100]
  8. Ann Med Exp Biol Fenn. 1973 Mar;51(3):118-24 [PMID: 4590099]
  9. J Clin Psychiatry. 2003 Jan;64(1):20-9 [PMID: 12590619]
  10. J Clin Pharmacol. 1990 Aug;30(8):748-54 [PMID: 2401754]
  11. Eur J Clin Pharmacol. 1976 Sep 30;10(5):331-5 [PMID: 789083]
  12. Acta Pharmacol Toxicol (Copenh). 1986 Mar;58(3):182-6 [PMID: 3716812]
  13. Int J Clin Pharmacol Ther. 2002 Jul;40(7):304-9 [PMID: 12139207]
  14. J Sleep Res. 2000 Sep;9(3):233-41 [PMID: 11012861]
  15. J Clin Psychiatry. 1996;57 Suppl 5:38-44 [PMID: 8647791]
  16. Alcohol. 1993 Jul-Aug;10(4):269-74 [PMID: 8397877]
  17. Eur J Clin Pharmacol. 1974 Aug 23;7(5):337-42 [PMID: 4607750]
  18. Acta Otolaryngol. 1974 Jul-Aug;78(1-2):59-64 [PMID: 4414636]
  19. Eur J Clin Pharmacol. 2000 Sep;56(6-7):453-8 [PMID: 11049006]
  20. J Stud Alcohol. 2004 Jul;65(4):450-9 [PMID: 15376819]
  21. Alzheimer Dis Assoc Disord. 2001 Jan-Mar;15(1):10-20 [PMID: 11236820]
  22. Neurology. 1993 Dec;43(12):2448-56 [PMID: 8255438]
  23. Eur J Clin Pharmacol. 1992;43(1):61-6 [PMID: 1505611]
  24. Can J Clin Pharmacol. 2003 Summer;10(2):72-7 [PMID: 12879145]
  25. Br J Pharmacol. 1973 Mar;47(3):671P-672P [PMID: 4730878]
  26. Hum Psychopharmacol. 2004 Mar;19(2):135-9 [PMID: 14994325]
  27. Am J Public Health. 1990 Dec;80(12):1467-70 [PMID: 1978581]
  28. Drug Alcohol Rev. 2004 Sep;23(3):319-44 [PMID: 15370012]
  29. Psychopharmacology (Berl). 1999 Apr;143(4):373-9 [PMID: 10367554]
  30. J Clin Psychopharmacol. 2004 Apr;24(2):155-60 [PMID: 15206662]
  31. Can Fam Physician. 2005 Mar;51:372-9 [PMID: 15794022]
  32. Acta Pharmacol Toxicol (Copenh). 1976 Apr;38(4):382-92 [PMID: 773108]
  33. Intern Med J. 2002 Jul;32(7):297-304 [PMID: 12088346]
  34. Inj Prev. 2000 Jun;6(2):90-1 [PMID: 10875662]
  35. Alzheimer Dis Assoc Disord. 1997 Jun;11 Suppl 1:17-20 [PMID: 9194963]
  36. Pharmacol Biochem Behav. 1998 Apr;59(4):917-23 [PMID: 9586849]
  37. Biol Psychiatry. 2004 May 15;55(10):1013-22 [PMID: 15121486]
  38. Ann Epidemiol. 1995 May;5(3):239-44 [PMID: 7606314]
  39. J Neurol Neurosurg Psychiatry. 1993 Aug;56(8):910-3 [PMID: 8102393]
  40. Psychopharmacologia. 1975;40(4):279-84 [PMID: 238256]
  41. Pharmacol Toxicol. 1988 Nov;63(5):369-74 [PMID: 3070520]
  42. Ann Neurol. 1988 Dec;24(6):782-6 [PMID: 3207361]
  43. Eur J Clin Pharmacol. 1996;51(2):161-6 [PMID: 8911882]
  44. Neurology. 2005 Sep 27;65(6):843-50 [PMID: 16186521]
  45. Clin Pharmacol Ther. 1974 Apr;15(4):368-73 [PMID: 4595291]
  46. J Psychopharmacol. 2003 Sep;17(3):324-31 [PMID: 14513925]
  47. Accid Anal Prev. 2006 Jan;38(1):28-34 [PMID: 16054104]
  48. Pharmacol Toxicol. 1994 Aug;75(2):91-8 [PMID: 7971743]
  49. Psychopharmacology (Berl). 2005 Oct;181(4):790-8 [PMID: 16025317]
  50. Am J Epidemiol. 1992 Oct 1;136(7):873-83 [PMID: 1442753]
  51. Sleep Med. 2003 Nov;4(6):553-61 [PMID: 14607350]
  52. Invest Radiol. 1986 Sep;21(9):717-9 [PMID: 3533834]
  53. J Am Geriatr Soc. 2006 Dec;54(12):1809-24 [PMID: 17198485]
  54. Pharmacol Biochem Behav. 1984;21 Suppl 1:57-64 [PMID: 6240662]
  55. Ergonomics. 1983 Nov;26(11):1055-61 [PMID: 6662099]
  56. Pharmacol Toxicol. 1990 Jul;67(1):77-80 [PMID: 2395820]
  57. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 2):1034-9 [PMID: 1979799]
  58. Public Health Rep. 1995 May-Jun;110(3):240-5 [PMID: 7610210]
  59. Hum Psychopharmacol. 2003 Jun;18(4):261-9 [PMID: 12766930]
  60. Eur J Clin Pharmacol. 1994;46(3):215-20 [PMID: 7915235]
  61. Epidemiology. 1994 Nov;5(6):591-8 [PMID: 7841240]
  62. CNS Drugs. 2004;18(1):37-48 [PMID: 14731058]
  63. J Clin Psychiatry. 1982 Dec;43(12 Pt 2):45-55 [PMID: 6130073]
  64. Sleep Med Rev. 2004 Aug;8(4):309-25 [PMID: 15233958]
  65. Alcohol Clin Exp Res. 1999 May;23(5):815-21 [PMID: 10371400]
  66. BMJ. 2004 Mar 6;328(7439):558-9 [PMID: 14732760]
  67. Soc Psychiatry Psychiatr Epidemiol. 2005 Oct;40(10):799-807 [PMID: 16179967]

MeSH Term

Automobile Driving
Computer Simulation
Humans
Mental Disorders
Meta-Analysis as Topic
Psychomotor Performance
Psychotropic Drugs
Task Performance and Analysis

Chemicals

Psychotropic Drugs

Word Cloud

Created with Highcharts 10.0.0drivingstudiespsychotropicmedicationsimpairmenteffectstimemotorvehicleTCAshoweverassessingabilitiesreviewresearchcomputer-simulatedvarioussamplecommontrackingreactionerrorsDrivingcentralfunctionalautonomypatientspsychiatricillnessesmanydeleteriousbenzodiazepinestypicalantipsychoticstricyclicantidepressantshumanskillsliteraturelittleattentionpaidaffectsabilityComputerisedsimulatorsofferlaboratory-basedmethodspecificstandardisedcontrolledsafemannerpurposepresentarticleundertakento-datesearchdatabasesincludingMEDLINEEMBASEPsycInfoconductedForty-onearticlesimpactpsychotropicsidentifiedpooledtotalnumbersubjectsassessedsimulator1336meansize3036[SD358]outcomemeasuresspeedsteeringdeviationlateralpositionlanedriftingbrakingaccuracyegturningcoordinationgapacceptancesignallingfollowingdistancecollisionsresultsquitevariabledrug-relatedimpairmentsincludedBenzodiazepinescommonlyassociatedalthoughleveldependentpopulationstudieddosetestingrelativedrugadministrationComputer-simulatedprovidesusefultoolpsychotropic-relatedLimitationscurrentlyavailabledataincludelackgeneralisabilitystandardisationsmallsizesImpactsimulateddriving:critical

Similar Articles

Cited By